ReviewImmune network2017
Host-microbial Cross-talk in Inflammatory Bowel Disease.
Review in Immune network, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.
- Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention.Frontiers in immunology · 2018Pooled it
- Effects of Mixed Nut Consumption on Blood Glucose, Insulin, Satiety, and the Microbiome in a Healthy Population: A Pilot Study.Journal of medicinal food · 2023Trial
- Microbiome-mediated regulation of pathogen virulence: Molecular mechanisms and clinical implications.Virulence · 2026Review
- Metagenomic Profiling of the Gut Microbiome in Age-Related Macular Degeneration-A Pilot Study.Biomedicines · 2026Article
- A longitudinal comparative analysis of serum metabolomic signatures in children with SARS-CoV-2 infection and MIS-C.Communications medicine · 2026Article
- Milk Kefir Beverage Improves Histomorphometry, Reduces Inflammatory Infiltrates and Desulfovibrio and Increases Lactobacillus in IL-10Journal of food science · 2026Article
- Segmented filamentous bacteria are associated with disease activity in children with inflammatory bowel disease.Frontiers in pediatrics · 2026Article
- Azithromycin alters the microbiome composition, function and resistome in women with Chlamydia trachomatis infections.NPJ biofilms and microbiomes · 2025Article
- Intestinal Goblet Cell-Expressed Reg4 Ameliorates Intestinal Inflammation Potentially by Restraining Pathogenic Escherichia coli Infection.Probiotics and antimicrobial proteins · 2025Article
- Gut Permeability and Microbiota in Parkinson's Disease: Mechanistic Insights and Experimental Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.Journal of bacteriology · 2025Review
- Anti-Inflammatory and Neuroprotective Effects ofMarine drugs · 2025Review
- Gut reactions and gut instincts: regulation of intestinal homeostasis by receptor guanylyl cyclase C (GC-C).The Biochemical journal · 2025Review
- Overview of Microorganisms: Bacterial Microbiome, Mycobiome, Virome Identified Using Next-Generation Sequencing, and Their Application to Ophthalmic Diseases.Microorganisms · 2025Review
- Microbiome composition and metabolic pathways in shallow and deep periodontal pockets.Scientific reports · 2025Article
- Impact of Microbiota Diversity on Inflammatory Bowel Disease.Microorganisms · 2025Article
- Dysbiosis of gut microbiota in C57BL/6-Lepem1hwl/Korl mice during microplastics-caused hepatic metabolism disruption.PloS one · 2025Article
- Mechanisms of Lushi Runzao decoction in Treating Sjögren's syndrome by remodeling gut flora to regulate bile acid and short-chain fatty acid metabolism.Frontiers in pharmacology · 2025Article
- Exploring the microbiota-gut-brain axis: impact on brain structure and function.Frontiers in neuroanatomy · 2025Review
- Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A vast community of commensal microorganisms, commonly referred to as the gut microbiota, colonizes the gastrointestinal tract (GI). The involvement of the gut microbiota in the maintenance of the gut ecosystem is two-fold: it educates host immune cells and protects the host from pathogens. However, when healthy microbial composition and function are disrupted (dysbiosis), the dysbiotic gut microbiota can trigger the initiation and development of various GI diseases, including inflammatory bowel disease (IBD). IBD, primarily includes ulcerative colitis (UC) and Crohn's disease (CD), is a major global public health problem affecting over 1 million patients in the United States alone. Accumulating evidence suggests that various environmental and genetic factors contribute to the pathogenesis of IBD. In particular, the gut microbiota is a key factor associated with the triggering and presentation of disease. Gut dysbiosis in patients with IBD is defined as a reduction of beneficial commensal bacteria and an enrichment of potentially harmful commensal bacteria (pathobionts). However, as of now it is largely unknown whether gut dysbiosis is a cause or a consequence of IBD. Recent technological advances have made it possible to address this question and investigate the functional impact of dysbiotic microbiota on IBD. In this review, we will discuss the recent advances in the field, focusing on host-microbial cross-talk in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.